Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

Nature Medicine

Volumn 9, Issue 3, 2003, Pages 279-286

  Brentjens, Renier J ^a   Latouche, Jean Baptiste ^a   Santos, Elmer ^a   Marti, Francesc ^b   Gong, Michael C ^a   Lyddane, Clay ^a   King, Philip D ^b   Larson, Steven ^a   Weiss, Mark ^a   Rivière, Isabelle ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; INTERLEUKIN 15; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL DESTRUCTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; ANTIGENS, CD80; B-LYMPHOCYTES; BONE MARROW; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 0037348324     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm827     Document Type: Article

References (45)

1. Collins, R.H. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433-444 (1997).
2. Riddell, S.R., Murata, M., Bryant, S. & Warren, E.H. T-cell therapy of leukemia. Cancer Control 9, 114-122 (2002).
3. Papadopoulos, E.B. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185-1191 (1994).
4. Savoldo, B., Heslop, H.E. & Rooney, C.M. The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients. Leukemia Lymphoma 39, 455-464 (2000).
5. Melief, C.J. et al. Strategies for immunotherapy of cancer. Adv. Immunol. 75, 235-282 (2000).
6. Sadelain, M., Rivièra, I. & Brentjens, R. Targeting tumors with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45 (2003).
7. Eshhar, Z. et al. The T-body approach: potential for cancer immunotherapy. Springer Semin. Immunopathol. 18, 199-209 (1996).
8. Schumacher, T.N. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2, 512-519 (2002).
9. Uckun, F.M. et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13-29 (1988).
10. Gong, M.C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplosia 1, 123-127 (1999).
11. Latouche, J.B. & Sadelain, M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol. 18, 405-409 (2000).
12. Maher, J., Brentjens, R.J, Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR-ζ/CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002).
13. Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001).
14. Rossi, E. et al. ζ chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 10, 494-497 (1996).
15. Chen, X. et al. Impaired expression of the CD3-ζ chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br. J. Haemotol. 111, 817-825 (2000).
16. +T cell adoptive immunotherapy. Immunity 13, 265-276 (2000).
17. Ochsenbein, A.F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
18. Sadelain, M. & Rivière, I. Sturm und Drang over suicidal lymphocytes. Mol. Ther. 5, 655-657 (2002).
19. Dudley, M.E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251 (2002).
20. Boussiotis, V.A., Lee, B.J., Freeman, G.J., Gribben, J.G. & Nadler, L.M. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J. Immunol. 159, 3156-3167 (1997).
21. Vella, A.T. et al. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J. Immunol. 158, 4714-4720 (1997).
22. Brocker, T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999-2001 (2000).
23. Fehniger, T.A., Cooper, M.A. & Caligiuri, M.A. Interteukin-2 and interteukln-15: immunotherapy for cancer. Cytokine Growth Factor Rev. 13, 169-183 (2002).
24. Waldmann, T.A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
25. Bulfone-Paus, S. et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat. Med. 3, 1124-1128 (1997).
26. Marks-Konczalik, J. et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97, 11445-11450 (2000).
27. Li, X.C. et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7, 114-118 (2001).
28. + T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
29. + memory T cells by opposing cytokines. Science 288, 675-678 (2000).
30. Oppenheimer-Marks, N., Brezinschek, R.I., Mohamadzadeh, M., Vita, R. & Lipsky, P.E. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells in vitro and in the SCID mouse-human rheumatoid arthritis model in vivo. J. Clin. Invest. 101, 1261-1272 (1998).
31. + human memory T cells. J. Immunol. 165, 716-724 (2000).
32. Peled, A. et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848 (1999).
33. Burger, J.A., Burger, M. & Kipps, T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94, 3658-3667 (1999).
34. Blazar, B.R. et al. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J. Immunol. 159, 3460-3473 (1997).
35. Maric, M., Zheng, P., Sarma, S., Guo, Y. & Liu, Y. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. Cancer Res. 58, 3376-3384 (1998).
36. Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619-626 (1998).
37. Geiger, T.L., Nguyen, P., Leitenberg, D. & Flavell, R.A. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98, 2364-2371 (2001).
38. Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3-ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J. Immunol. 167, 6123-6131 (2001).
39. Haynes, N.M. et al. Single-chain antigen recognition receptors that co-stimulate potent rejection of established experimental tumors. Blood 100, 3155-3163 (2002).
40. Greenlee, R.T., Hill-Harmon, M.B., Murray, T. & Thun, M. Cancer Statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
41. Byrd, J.C. et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19, 2153-2164 (2001).
42. Gallardo, H.F., Tan, C. & Sadelain, M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther. 4, 1115-1119 (1997).
43. Rivière, I., Brose, K. & Mulligan, R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92, 6733-6737 (1995).
44. Tedder, T.F. & Isaacs, C.M. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J. Immunol. 143, 712-717 (1989).
45. 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc. Natl. Acad. Sci. USA 99, 3030-3035 (2002).